A Phase 3 Randomized, Placebo-Controlled Trial Evaluating Memantine (IND# 149832) for Neurocognitive Protection in Children Undergoing Cranial Radiotherapy as Part of Treatment for Primary Central Nervous System Tumors (ACCL2031)

The Pediatric Hematology/Oncology Division at the University of Virginia is conducting a clinical research study for pediatric patients who have been recently diagnosed with a brain tumor and are planning to undergo radiation therapy. This phase III trial compares memantine to usual treatment in treating patients with brain tumors that are newly diagnosed or have come back (recurrent). Memantine may block receptors (parts of nerve cells) in the brain known to contribute to a decline in cognitive function.

A Phase 2 Trial of Chemotherapy followed by Response Based Whole Ventricular & Spinal Canal Irradiation (WVSCI) for Patients with Localized Non-Germinomatous Central Nervous System Germ Cell Tumor (ACNS2021)

The Pediatric Hematology/Oncology Division at the University of Virginia is conducting a clinical research study for pediatric patients who have been recently diagnosed with a brain tumor. This phase II trial studies the best approach to combine chemotherapy and radiation therapy (RT) based on the patient's response to induction chemotherapy in patients with non-germinomatous germ cell tumors (NGGCT) that have not spread to other parts of the brain or body (localized).

A Phase 3 Randomized Controlled Trial Comparing Open vs Thoracoscopic Management of Pulmonary Metastases in Patients with Osteosarcoma (AOST2031)

The Pediatric Hematology/Oncology Division at the University of Virginia is conducting a clinical research study for pediatric patients who have been diagnosed with osteosarcoma that has spread to the lung. This phase III trial compares the effect of open thoracic surgery (thoracotomy) to thoracoscopic surgery (video-assisted thoracoscopic surgery or VATS) in treating patients with osteosarcoma that has spread to the lung (pulmonary metastases).

A Phase 3 Randomized Trial for Patients with de novo AML Comparing Standard Therapy Including Gemtuzumab Ozogamicin (GO) to CPX-351 with GO, and the Addition of the FLT3 Inhibitor Gilteritinib for Patients with FLT3 Mutations (AAML1831)

The Pediatric Hematology/Oncology Division at the University of Virginia is conducting a clinical research study for pediatric patients who have been recently diagnosed with acute myeloid leukemia (AML). This phase III trial compares standard chemotherapy to therapy with liposome-encapsulated daunorubicin-cytarabine (CPX-351) and/or gilteritinib for patients with newly diagnosed acute myeloid leukemia with or without FLT3 mutations.

A phase II study of GT103 in combination with pembrolizumab in refractory, metastatic non-small cell lung cancer (HCRN LUN21-497)

The University of Virginia Cancer Center is conducting a clinical research study for patients who are adults ages 18 and over, and have refractory, recurrent, or advanced non-small cell lung cancer. The purpose of this study to evaluate an investigational drug, GT103 in combination with an immunotherapy drug, pembrolizumab. The safety and effects of the investigational treatment will be assessed for this study.

A phase II multicenter study of lenvatinib plus everolimus versus cabozantinib in patients with metastatic renal cell carcinoma that progressed on a PD-1/PD-L1 checkpoint inhibitor

The University of Virginia Comprehensive Cancer Center seeks adults ages 18 and over with metastatic renal cell carcinoma who have received 1-2 prior forms of treatment for this disease for a research study. The most recent form of treatment must have included a PD-1/PD-L1 checkpoint inhibitor. The purpose of the study is to compare the effectiveness of two different FDA-approved treatments: lenvatinib plus everolimus, and cabozantinib. The treatment that you will receive will be randomly assigned, and both you and the study doctor will know what treatment group you are a part of.